Wolff C, Frank J, Poblete-Gutiérrez P

Language: Spanish
References: 23
Page: 289-295
PDF size: 65.57 Kb.

ABSTRACT

Variegate porphyria (VP) results from a hereditary deficiency of protoporphyrinogen oxidase (PPOX) that is transmitted in an autosomal dominan fashion. The diagnosis is based on the clinical symptoms and is confirmed biochemically. Sometimes, however, these diagnostic tools reveal limitations in establishing the definitive diagnosis of the prevailing type of acute porphyria. In these patients, molecular genetic analyses can be useful. We performed molecular genetic studies in 13 Chilean families by PCR amplification of the PPOX gene, conformation sensitive gel electrophoresis, and automated DNA sequencing. In five symptomatic patients from different families, respectively, the biochemical data confirmed the diagnosis of VP. In seven other families, however, the biochemical studies were not conclusive. Furthermore, the original biochemical analysis in one clinically severely affected patient from a further family even suggested the diagnosis of erythropoietic protoporphyria (EPP). Beside the respective index patients, we studied 78 asymptomatic family members and 50 healthy, unrelated individuals for control purposes. In five families, the previous diagnosis of VP could be confirmed genetically. Further, half of the asymptomatic relatives revealed a mutation in the PPOX gene, consisting of three missense mutations and two deletion mutations. Mutation R168H that had been already described previously in German VP families was found in a Chilean family of German origin. Further, two novel missense mutations, designated L74P and G232S, could be detected. In four Chilean families, we found the deletion 1330deICT that had also been previously described in three Swedish VP families. The second deletion, 1239delTACAC, has not been described anywhere else but Chile and could be identified in seven families. One patient who was initially diagnosed with EPP turned out to be a compound heterozygote for mutations on both alleles of the PPOX gene. In conclusion, our molecular genetic analyses unequivocally confirmed the diagnosis of VP in seven families who originally had revealed inconclusive biochemical data. Further, early genetic analysis allows for the identification of asymptomatic mutation carriers, thereby offering the possibility of adequate counselling and the prevention of potentially life-threatening acute porphyric attacks.

REFERENCES

1. Poblete-Gutiérrez P, Méndez M, Wiederholt T. et al. Diagnosis and treatment of the acute porphyrias: an interdisciplinary challenge. Skin Pharmacol Appl Skin Physiol 2001; 14: 393-400.

2. Badminton MN, Elder GH. Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 2005; 28: 277-86.

3. 3 . Armas R, Wolff C, Krause P, et al. The hepatic porphyrias: experience with 105 cases. Rev Med Chil 1992; 120: 259-66.

4. Kauppinen R. Porphyrias. Lancet 2005; 365: 241-52.

5. Sandberg S, Brun A, Skadberg O, Iversen IR, Benestad Y, Danielsen OK. Acute intermittent porphyria is a difficult diagnosis especially in children. Tidsskr Nor Laegeforen 2001; 121: 2822-5.

6. Norris PG, Elder GH, Hawk JL. Homozygous variegate porphyria: a case report. Br J Dermatol 1990; 122: 253-7.

7. Hift RJ, Meissner PN, Todd G, et al. Homozygous variegate porphyria: an evolving clinical syndrome. Postgrad Med J 1993; 69: 781-6.

8. Frank J, McGrath J, Lam H, et al. Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J Invest Dermatol 1998; 110: 452-5.

9. De Villiers PJN, Kotze MJ, Van Hereden CJ, et al. Overrepresentation of the founder PPOX gene mutation R59W in a South African patient with severe clinical manifestation of porphyria. Ex Dermatol 2005; 14: 50-5.

10. Frank J, Aita VM, Ahamad W, Lam H, Wolff C, Christiano AM. Identification of a founder mutation in the protoporphyrinogen oxidase gene in variegate porphyria patients from Chile. Hum Hered 2001; 51: 160-8.

11. da Silva V, Simonin D, Deybach JC, Puy H, Nordmann Y. Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 1995; 238: 163-8.

12. Grandchamp B, Puy H, Lamoril J, Deybach JC, Nordmann Y. Review: molecular pathogenesis of hepatic acute porphyrias. Gastroenterol Hepatol 1996; 11: 1046-52.

13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

14. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: Evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 1993; 90: 10325-9.

15. Poblete-Gutiérrez P, Wolff C, Farías R, Frank J. .A Chilean boy with severe photosensitivity and finger shortening: The first case of ho mozygous variegate porphyria in South America. Brit J Dermatol 2006; 154: 368-71.

16. Frank J, Jugert FK, Breitkopf C, Goerz G, Merk HF, Christiano AM. Recurrent missense mutation in the protoporphyrinogen oxidase gene underlies variegate porphyria. Am J Med Genet 1998; 79: 22-6.

17. Whatley SD, Puy H, Morgan RR. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 1999; 65: 984-94.

18. Frank J, McGrath JA, Poh-Fitzpatrick MB, Hawk JL, Christiano AM. Mutations in the translation initiation codon of the protoporphyrinogen oxidase gene underlie variegate porphyria. Clin Exp Dermatol 1999; 24: 296-301.

19. Deybach JC, Puy H, Robréau AM, et al. Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. Hum Mol Genet 1996; 5: 407-10.

20. Wiman A, Harper P, Floderus Y. Nine novel mutations in the protoporphyrinogen oxidase gene in Swedish families with variegate porphyria. Clin Genet 2003; 64: 122-30.

21. Bickers D, Frank J. The Porphyrias. In: Dermatology in general medicine. Fitzpatrick TB, Freedkey IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz ST (Eds.). 6a. Ed. New York: MacGraw Hill; 2003, p. 1435-66.

22. Hift RJ, Meissner PM. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005; 84: 48 - 60.

23. Moore MR, Hift RJ. Drugs in the acute porphyrias—toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand) 1997; 43: 89-94.